- Home
- SGC vs MIST Comparison
SGC vs MIST Comparison
Compare SGC & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGC | MIST |
|---|---|---|
| Founded | 1920 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.2M | 176.3M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SGC | MIST |
|---|---|---|
| Price | $10.12 | $1.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $17.33 | $8.50 |
| AVG Volume (30 Days) | 30.4K | ★ 1.2M |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.48% | N/A |
| EPS Growth | N/A | ★ 51.80 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $566,184,000.00 | N/A |
| Revenue This Year | $0.73 | N/A |
| Revenue Next Year | $3.38 | N/A |
| P/E Ratio | $22.33 | ★ N/A |
| Revenue Growth | ★ 0.09 | N/A |
| 52 Week Low | $8.30 | $0.63 |
| 52 Week High | $14.46 | $3.06 |
Technical Indicators
Market Signals| Indicator | SGC | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 49.14 | 50.25 |
| Support Level | $9.72 | $1.62 |
| Resistance Level | $10.48 | $1.79 |
| Average True Range (ATR) | 0.43 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 36.53 | 90.00 |
Price Performance
Historical ComparisonAbout SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).